Gilead

• Remdesivir not recommended for hospitalized coronavirus patients, WHO says

  The advice is another setback for the drug, which grabbed worldwide attention as a potentially effective treatment for COVID-19 in the summer after early trials showed some promise.

  World

  Nov 19, 2020
  
• Remdesivir cut coronavirus recovery time by 5 days, company’s final study suggests

  The antiviral drug, which was recently used to treat U.S. President Donald Trump, also appeared to reduce the risk of death in some patients.

  Health

  Oct 8, 2020
• Advertisement
• U.S. buys up worldwide stock of remdesivir, drug seen as potential COVID-19 treatment

  The Department of Health and Human Services has secured more than 500,000 treatment courses of the drug from its sole manufacturer Gilead for American hospitals through September.

  Health

  Jun 30, 2020
• Advertisement
• Coronavirus drug remdesivir to cost $2,340 per patient in the U.S.

  The amount that patients pay out of pocket depends on insurance, income and other factors.

  World

  Jun 29, 2020
• Remdesivir, hailed as potential COVID-19 treatment, gets emergency U.S. FDA green light

  An emergency use authorization by the FDA is not the same as drug approval.

  Health

  May 1, 2020
• Experimental drug proven effective against coronavirus, biotech company says

  Gilead Sciences’s remdesivir would be the first treatment to pass such a test against the virus, which has killed more than 218,000 people since it emerged late last year in China.

  Science

  Apr 29, 2020
• Coronavirus: Drug trial sees ‘encouraging’ results but researchers say more study needed

  Nearly 70 per cent of patients tested in the U.S., Europe, Canada and Japan improved after taking the Gilead Sciences drug remdesivir, but eight of the patients worsened while seven died.

  Health

  Apr 10, 2020